SG11201701690WA - Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea - Google Patents
Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrheaInfo
- Publication number
- SG11201701690WA SG11201701690WA SG11201701690WA SG11201701690WA SG11201701690WA SG 11201701690W A SG11201701690W A SG 11201701690WA SG 11201701690W A SG11201701690W A SG 11201701690WA SG 11201701690W A SG11201701690W A SG 11201701690WA SG 11201701690W A SG11201701690W A SG 11201701690WA
- Authority
- SG
- Singapore
- Prior art keywords
- elsiglutide
- including chemotherapy
- induced diarrhea
- treat gastrointestinal
- gastrointestinal mucositis
- Prior art date
Links
- 206010012735 Diarrhoea Diseases 0.000 title 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 229950001278 elsiglutide Drugs 0.000 title 1
- 208000018925 gastrointestinal mucositis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048520P | 2014-09-10 | 2014-09-10 | |
| PCT/IB2015/001922 WO2016038455A1 (en) | 2014-09-10 | 2015-09-02 | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701690WA true SG11201701690WA (en) | 2017-04-27 |
Family
ID=54548212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701690WA SG11201701690WA (en) | 2014-09-10 | 2015-09-02 | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160067311A1 (https=) |
| EP (1) | EP3191115A1 (https=) |
| JP (1) | JP2017532308A (https=) |
| KR (1) | KR20170052661A (https=) |
| CN (1) | CN107073081A (https=) |
| AR (1) | AR103119A1 (https=) |
| AU (1) | AU2015313919A1 (https=) |
| BR (1) | BR112017004577A2 (https=) |
| CA (1) | CA2959110A1 (https=) |
| CL (1) | CL2017000563A1 (https=) |
| EA (1) | EA201790552A1 (https=) |
| IL (1) | IL250928A0 (https=) |
| MA (1) | MA40623A (https=) |
| MX (1) | MX2017003166A (https=) |
| PH (1) | PH12017500426A1 (https=) |
| SG (1) | SG11201701690WA (https=) |
| TW (1) | TW201613634A (https=) |
| WO (1) | WO2016038455A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170087216A1 (en) * | 2015-09-17 | 2017-03-30 | Helsinn Healthcare Sa | Therapeutic Uses of Elsiglutide |
| US11389424B2 (en) | 2017-03-09 | 2022-07-19 | Napo Pharmaceuticals, Inc. | Methods and compositions for treating chemotherapy-induced diarrhea |
| BR112019026711A2 (pt) * | 2017-06-16 | 2020-06-30 | Zealand Pharma A/S | regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2) |
| MX2022016367A (es) * | 2020-06-19 | 2023-01-30 | Napo Pharmaceuticals Inc | Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia. |
| CN115054683B (zh) * | 2022-05-19 | 2023-06-09 | 唐颢 | 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101163483A (zh) * | 2005-04-22 | 2008-04-16 | 诺瓦西股份有限公司 | 使用活性维生素d化合物或其模拟物治疗、预防和缓解与化疗和放疗有关的肺部疾患 |
| DE602006020123D1 (de) * | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| EP2314616A1 (en) * | 2009-10-23 | 2011-04-27 | Ferring B.V. | Peptidic GLP-2 agonists |
-
2015
- 2015-09-01 US US14/842,250 patent/US20160067311A1/en not_active Abandoned
- 2015-09-02 EP EP15795220.1A patent/EP3191115A1/en not_active Withdrawn
- 2015-09-02 CA CA2959110A patent/CA2959110A1/en not_active Abandoned
- 2015-09-02 MA MA040623A patent/MA40623A/fr unknown
- 2015-09-02 KR KR1020177009656A patent/KR20170052661A/ko not_active Withdrawn
- 2015-09-02 BR BR112017004577A patent/BR112017004577A2/pt not_active Application Discontinuation
- 2015-09-02 SG SG11201701690WA patent/SG11201701690WA/en unknown
- 2015-09-02 JP JP2017513522A patent/JP2017532308A/ja active Pending
- 2015-09-02 MX MX2017003166A patent/MX2017003166A/es unknown
- 2015-09-02 AU AU2015313919A patent/AU2015313919A1/en not_active Abandoned
- 2015-09-02 CN CN201580060760.4A patent/CN107073081A/zh active Pending
- 2015-09-02 WO PCT/IB2015/001922 patent/WO2016038455A1/en not_active Ceased
- 2015-09-02 EA EA201790552A patent/EA201790552A1/ru unknown
- 2015-09-04 TW TW104129362A patent/TW201613634A/zh unknown
- 2015-09-09 AR ARP150102872A patent/AR103119A1/es unknown
-
2017
- 2017-03-05 IL IL250928A patent/IL250928A0/en unknown
- 2017-03-07 PH PH12017500426A patent/PH12017500426A1/en unknown
- 2017-03-08 CL CL2017000563A patent/CL2017000563A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017532308A (ja) | 2017-11-02 |
| IL250928A0 (en) | 2017-04-30 |
| KR20170052661A (ko) | 2017-05-12 |
| TW201613634A (en) | 2016-04-16 |
| MA40623A (fr) | 2016-03-17 |
| CL2017000563A1 (es) | 2017-09-29 |
| US20160067311A1 (en) | 2016-03-10 |
| WO2016038455A1 (en) | 2016-03-17 |
| MX2017003166A (es) | 2017-06-19 |
| CA2959110A1 (en) | 2016-03-17 |
| BR112017004577A2 (pt) | 2018-01-23 |
| AR103119A1 (es) | 2017-04-19 |
| PH12017500426A1 (en) | 2017-07-31 |
| AU2015313919A1 (en) | 2017-03-16 |
| EP3191115A1 (en) | 2017-07-19 |
| EA201790552A1 (ru) | 2017-08-31 |
| CN107073081A (zh) | 2017-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272130B (en) | Inhibitors of specific lysine demethylase-1 | |
| IL250876B (en) | Inhibitors of specific lysine demethylase-1 | |
| IL248505B (en) | Inhibitors of specific lysine demethylase-1 | |
| SG11201609265RA (en) | Characterizing states of subject | |
| IL249733B (en) | Inhibitors of specific lysine demethylase-1 | |
| IL252873A0 (en) | The l-tartrate salt of pridopidine | |
| PL3261721T3 (pl) | Stososowanie pridopidyny w celu poprawy pamięci | |
| IL249876A0 (en) | Inhibitors of specific lysine demethylase-1 | |
| GB2541833B (en) | Improvements to implant surfaces | |
| PL3223837T3 (pl) | Lactobacillus do zastosowania jako probiotyk | |
| SI3845221T1 (sl) | Trdne oblike sofosbuvirja | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| TWM489225U (en) | Leakage-stop structure of five-pass valve ball pad | |
| IL246979A0 (en) | Crystalline forms of sofosbuvir | |
| PT3122349T (pt) | Composições para o tratamento da autodigestão | |
| IL250928A0 (en) | Use of eliglutide to treat gastrointestinal mucosal inflammation including chemotherapy-induced diarrhea | |
| GB2541587B (en) | Observation mask of dermatoscope | |
| IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| HK1235015A1 (en) | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea | |
| GB201410118D0 (en) | Early diagnosis of leptospire | |
| IL249332A0 (en) | Crystalline forms of sofosbuvir | |
| ZA201504639B (en) | Treatment of water | |
| GB201418410D0 (en) | use of compositions of matter | |
| GB201405157D0 (en) | Theory of international law |